Article Topic
Compounded GLP-1 crisis: what patients and policymakers need to know
Telehealth companies and mass compounders are selling knockoff GLP-1s to patients who believe they’re getting the real thing. They aren’t.
[...]Forfeiture Order, USA v Rebecca Fadanelli, September 2026
United States District Court District of Massachusetts USA v Rebecca Fadanelli Forfeiture order Filed September 2026 Read the document. (opens in new tab)
[...]Government’s Sentencing Memo, USA v Rebecca Fadanelli, August 2026
United States District Court District of Massachusetts USA v Rebecca Fadanelli Government’s Sentencing Memo Filed August 2026 Read the document. (opens in new tab)
[...]Pill press update: February to July 2026
Between February and July, the media covered pill press seizures in 13 states and customs forfeiture records reported seizures of 16 pill presses, six capsule-filling machines, and over 300 pill press parts, dies, and molds. Learn more about the last six months in pill press news.
[...]Tens of thousands of units of retatrutide: May & June 2026 freight fraud report
May and June 2026 saw thousands of shipments of drugs imported into the US, including weight loss drugs and antibiotics. We studied these shipments to learn more about their manufacturers and contents.
[...]He just wanted to get back to work: a simple backache ended in tragedy
35-year-old Tyreek Lewis just wanted his back pain to stop, but pain relief would mean time off from work, hours of tests, and extra appointments. So he took what looked like a simple shortcut. It killed him, and altered his family’s life forever.
[...]Plea Agreement, USA v Jon Paul Dadaian
United States District Court District of New Jersey USA v Jon Paul Dadaian Plea Agreement Filed May 2022 Read the document.
[...]Mass drug compounding poses serious risks to patients
Drug compounding is intended to meet individual patient needs or temporarily bridge shortages — but the GLP-1 market has broken that model. T
[...]Statement from Partnership for Safe Medicines on new litigation alleging illegal distribution of retatrutide
Partnership for Safe Medicines Executive Director Shabbir Imber Safdar released the following statement on the six lawsuits Eli Lilly filed today against businesses it accuses of illegally distributing unapproved copies of its investigational drug, retatrutide. Lilly is suing these defendants for illegal distribution of retatrutide including, in one case, a licensed 503A compounding pharmacy.
[...]Statement from Partnership for Safe Medicines on the appeals court’s decision in Gilead Sciences v. Meritain Health
The appeals court’s decision in Gilead Sciences v. Meritain Health is unambiguous: you cannot import untraceable medicine with foreign-language labels, hand it to American patients, and call it equivalent to an FDA-approved medicine. Track-and-trace is a cornerstone of why the U.S. drug supply chain is the safest in the world, and it is not optional.
[...]